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The introduction of H2-receptor antagonists in the mid-1970s provided, for the
first time, acceptable medical therapy for acid-related diseases. Their short
duration of action and single receptor targeting, however, limited satisfactory
treatment of patients. Today the control of gastric acid secretion can be effec-
tively achieved by direct inhibition ofthe H+, K+-ATPase. Inhibition ofthe pro-
ton pump suppresses acid secretion independent ofthe routeofstimulation. Two
classes ofdrugs are able to inhibit the proton pump. First, the substituted benz-
imidazoles (proton pump inhibitors [PPIs]), which, due to their pKa of about 4,
accumulate in the acidic secretory canaliculus of the stimulated parietal cell.
Following conversion to acationic sulfenamide, they react with cysteines on the
extracytoplasmatic face of the H+, K+-ATPase subunit. Second, acid pump
antagonists (APAs) acting by K+-competitive and reversible binding to the gas-
tric proton pump, which is the final step for activation of acid secretion in the
parietal cell.
Onepossible class ofAPAs are imidazopyridines. BY841 was selected from this
class and is chemically a (8-(2-methoxycarbonylamino-6-methyl-phenylmethy-
lamino)-2,3-dimethyl-imidazo [1,2-a]-pyridine). In pharmacological experi-
ments such as pH-metry in the conscious, pentagastrin-stimulated fistula dog,
BY841 proved to be superior to both ranitidine and omeprazole by rapidly ele-
vating intragastric pH up to a value of6. The duration ofthis pH elevation in the
dog was dose-dependent.
As was predicted by the above-mentioned dog model, available clinical phase I
data confirm dose-dependent pharmacodynamics ofBY841 in man. Using both
acid output and continuous 24-hr pH measurements, a pronounced antisecreto-
ry effectofBY841 has been found. Actually, a single 50mg oral dose ofBY841
immediately elevated intragastric pH to about 6. Higher doses caused a dose-
dependent increase in duration ofthepH-elevation, without any further increase
in maximum pH values. Twice daily administration was more effective than
once a day administration ofthe samedaily dose. With both regimens, the dura-
tion ofthe pH-elevating effect of BY841 further increased upon repeated daily
administration. This demonstrates lack of tolerance development, the latter
being a well-known disadvantage of H -receptor antagonists. In comparison
with the standard dose of omeprazole, BY841 administered at a dose of50 mg
or 100 mg twice daily is markedly more effective on Day one oftreatment, and
both doses are at least as potent as omeprazole following repeated daily admin-
istration.
INTRODUCTION
The introduction of H2-receptor antagonists (H2RAs)b about 20 years ago provided,
for the first time, acceptable effective medical therapy for acid-related diseases. However,
due to their single receptortargeting, the acid-suppressing effect can be overcome by stim-
ulation via other pathways. Further shortcomings in patient treatment were development
aTo whom all correspondence should be addressed: W. Wurst, M.D., M.Sc., Byk Gulden, Byk-
Gulden-Str. 278467 Konstanz, Germany. Tel: 49-7531-84-2252; Fax: 49-7531-84-2474.
bAbbreviations: H2RA, H2-receptor antagonist, PPI, proton pump inhibitor; APA, acid pump antag-
onist; AUC, area under the curve; PSAO, pentagastrin-stimulated acid output.
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of tolerance and short duration of action combined with poor control of daytime acid
secretion.
The development ofsubstituted benzimidazoles, the so-called proton pump inhibitors
(PPIs) markedly improved the treatment of acid-related diseases. PPIs act by covalent
binding to the final step of gastric acid secretion, the gastric H+, K+-ATPase. Hence, in
contrast to H2RAs, suppression of intragastric acidity may not be overcome by stimula-
tion via any pathway. In general, the PPIs are weak base pro-drugs that accumulate only
in the acidic secretory canaliculus of the secreting parietal cell. There they are activated
by acid to cysteine-reactive sulphenamides. The PPIs have a short serum elimination half-
life ofabout one hour, but their covalentbinding provides a long-lasting inhibition ofacid
secretion. On the other hand, steady-state inhibition is reached only after 48 to 72 hours
on once daily dosing when a balance is struck between inhibition ofactive pumps and de
novo synthesis of new pumps.
The development ofanother class ofcompounds targeting the H+, K+-ATPase tries to
combine the advantages ofboth PPIs and H2RAs. These new drugs actby competing with
K+ on the outer surface ofthe enzyme. Due to theirreversible binding to the proton pump,
they are called acid pump antagonists (APAs). They are active in the absence ofacid secre-
tion and bind to specific sites in the membrane domain of the H+, K+-ATPase. This pre-
vents H+ ion transport. Treatment with APAs should thus provide a more rapid elevation
ofgastric pH than is found with PPIs, and the elevation ofpH should be greater than with
oral PPIs at least as long as the APA is present in blood above threshold . Further prolon-
gation of the acid-suppressing effect might be caused by high affinity of the drug to the
enzyme, and tolerance is not to be expected.
Therefore, APAs should provide excellent control of intragastric pH, hence faster
symptom remission and perhaps better clinical results in gastric acid-related diseases,
symptom relief and in combination therapy for Helicobacterpylori eradication.
APAs represent, apart from additional chemical structures, imidazopyridines (e.g.,
BY841) or quinolines (e.g., BY067/SK&F96067, BY574/SK&F97574), a great variety of
which have been tested pharmacologically. Based on preclinical and clinical phase I data,
BY841 has been chosen for further development and is currently in Phase II. This publi-
cation summarizes the data obtained so far for BY841, with particular focus on phase I
clinical trials.
PRECLINICAL
The gastric H+,K+-ATPase of the parietal cell extrudes protons from the cytoplasm
into the extracytoplasmic space in exchange for potassium, which is absorbed into the
cytoplasm. It belongs to the class of P-type ATPases. They are so-named because of the
phospho-enzyme intermediate that is formed during the hydrolysis of ATP. In order to
keep the reaction cycle ongoing, the enzyme has to be dephosphorylated by potassium
from the extracytoplasmic face of the pump. Due to the comparable molecular size,
ammonium can mimic potassium in activating the sodium, as well as the proton pump. If
ammonium is derivatized, leading to compounds with nitrogen containing heterocycles
(imidazopyridines, quinolines), inhibitors of the enzyme are obtained. The main charac-
teristics of these inhibitors are the competition for the K+-binding at the proton pump and
the reversibility of this binding (i.e., inhibition of the enzyme). The latter can be demon-
strated by dilution experiments. Due to these properties, compounds of this type are so-
called acid pump antagonists (APAs). The structural differences between the proton pump
and the sodium pump allow K+-competition by the APA at the proton pump only, where-
as the inhibition of the sodium pump is low and seems to be non-competitive (data not
shown). SCH28080 (Schering) was the first APA in preclinical and clinical development
followed by the chinoline derivatives BY067 and BY574.
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Table 1. IC50 values for proton pump and sodium pump at 1 mM K+.
Proton pump Sodium pump
(IgM) (gM)
BY067 1.9 60
BY574 1.5 95
BY841 0.04 63
W.A. Simon, unpublished data.
Table 2. Inhibition ofacid secretionED5O values after i.v. administration.
Ghosh Schild Rat Heidenhain Pouch Dog
(mg/kg) (mg/kg)
BY067 1.1 0.10
BY574 0.7 0.04
BY841 0.1 0.03
S. Postius, R. Riedel, unpublished data.
The inhibitory potency of antisecretory compounds is expressed in terms of their
IC50 values (i.e., the concentration of agent required to cause a 50 percent inhibition).
Thus, as can be seen from Table 1, BY841 has the lowest IC50 value and is therefore the
most potent of the three compounds. The ratio of the ICSO values for the sodium vs. the
proton pump as an index for the selectivity was at least one order ofmagnitude greater for
BY841 than forBY067 and BY574. Hence, BY841 has the greatest selectivity forthe pro-
ton pump (Table 1).
In both screening models, thepentagastrin-stimulated Ghosh Schild Rat and the hista-
mine stimulated Heidenhain Pouch Dog, BY841 proved to be the most potent compound
(Table 2, for methods see [1]).
pH-metry in the conscious and fasted pentagastrin-stimulated fistula dog (for meth-
ods, see [2]) BY841 proved to be superior to both ranitidine [3] and omeprazole by rapid-
ly elevating intragastric pH up to values ofabout 6 even after a single oral dose of about
10 mg/kg. The duration of this pH elevation in the dog was dose-dependent [3]. In this
experimental model, BY841 was also more effective than ranitidine in suppressing carba-
chol-stimulated acid secretion.
Due to its unique pH profile and potency, BY841 was chosen for further clinical
development. Its chemical structure is shown in Figure 1.
Figure 1: Chemical structure ofBY841.
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PHASE I CLINICAL TRIALS WITH BY841
Materials and Methods
All study protocols were approved by independent ethics committees, and written
informed consent by each volunteer was obtained prior to the start ofthe study.
In pH-metry studies, intragastric pH was continuously recorded over 24 hours using
a DL70 recorder (Sch6nfeld Datentechnik, Karlsruhe, Germany) and Ingold glass elec-
trodes M440 (Ingold, Urdorf, Switzerland).
Study 1: Single increasing oral doses, pH-metry
Healthy male subjects (n = 18) were admitted to the study and divided into three
groups ofsix subjects each. Their age ranged from 23 to 42 years (median: 27.5) and their
body weight, from 65 to 86 kg (median: 73).
Each subject was given two single oral doses ofBY841 in increasing orderwith inter-
posed placebo administration. There was a wash-out period ofat least one week between
two consecutive treatment days.
* Group 1: 10 mg, 20 mg, interposed placebo
* Group 2: 50 mg, 100 mg, interposed placebo
* Group 3: 200 mg, 400 mg, interposed placebo
Groups 1, 2 and 3 received treatment in that order and only after completion of the
treatment in the preceding group.
Safety and tolerability were assessed by vital signs, ECG, clinical laboratory and
adverse events. In Groups 2 and 3, intragastric pH was continuously recorded over 24
hours.
Study 2: Single increasing oral doses, pentagastrin-stimulated acidoutput (PSAO)
Healthy male subjects (n = 18), aged 18 to 44 years (median 32) with body weight of
between 61 and 97.5 kg (median 79.5) were divided into three groups ofsix subjects each.
Each subject was given two single oral doses of BY841 in increasing order with inter-
posed placebo administration. There was a wash-out period ofat least one week between
two consecutive treatment days.
* Group 1: 10 mg, 20 mg, interposed placebo
* Group 2: 50 mg, 100 mg, interposed placebo
* Group 3: 200 mg, 400 mg, interposed placebo
Groups 1, 2 and 3 received treatment in that order and only after completion of the
treatment in the preceding group.
Safety and tolerability were assessed by vital signs, ECG, clinical laboratory and
adverse events. Gastric acid output was assessed using the aspiration technique. A gastric
tube was inserted into the stomach, and its correct position was checked by the water
recovery method. Gastric acid secretion was stimulated by a continuous i.v. infusion of
pentagastrin (Peptavlon®, ICI, UK) at a rate of0.6jg/kg/hr, and gastric content was aspi-
rated and collected in 15-min aliquots from two to five hours post-dose. The volume of
the 15-min samples was measured and the H+ concentration was determined by titration
with 0.1 N NaOH up to a pH of 7. pH was measured by use of a pH meter (Radiometer
Kopenhagen). Acid output was calculated. Blood was withdrawn and BY841 serum con-
centrations were analyzed by HPLC.
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Study 3: Repeated oral once-daily and twice-daily doses, pH-metry
Healthy male subjects (n = 8), aged 19 to 41 years (median 35), with body weights of
between 65 and 96 kg (median 76) underwent the following two treatment periods ofnine
days each in randomized order:
Once-daily treatment:
* Day -2 and -1: Placebo once daily
* Day 1 to 7: 200 mg BY841 (in the morning)
Twice-daily treatment
* Day -2, -1: Placebo bid
* Day 1 to 7: 100 mg BY841 twice daily (in the morning and evening)
There was a wash-out period of at least two weeks between the treatment periods.
Safety and tolerability were assessed by vital signs, ECG, clinical laboratory and
adverse events. Intragastric pH was continuously recorded over24 hours on Day -2 (place-
bo) as well as on Day one and Day seven ofboth treatment periods. Blood was frequent-
ly withdrawn on Days one and seven ofboth periods and serum concentrations were ana-
lyzed by HPLC.
Study 4: repeated oral twice-daily doses vs. omeprazole, pH-metry
In a randomized single-blind three-period crossover study, 12 healthy male volun-
teers, aged 22 to 41 years (median 29), with body weights ofbetween 62 and 97 kg (medi-
an 83.5), completed the following treatment periods of seven days each:
* 50 mg BY841 twice daily (in the morning and in the evening)
* 100 mg BY841 twice daily (in the morning and in the evening)
* 20 mg omeprazole in the morning, placebo in the evening
Medication was filled in identical hard gelatin capsules. There was a wash-out peri-
od of at least one week between consecutive treatment periods.
Safety and tolerability were assessed by vital signs, ECG, clinical laboratory and
adverse events. Within one week before the start ofthe first treatment period, the subjects
underwent a baseline pH-metry. On Days one and seven of each treatment period, intra-
gastric pH was continuously recorded over 24 hours.
Analytics
Serum concentrations of BY841 were measured by a validated and specific reversed
phase gradient HPLC using fluorescence detection. Workup of samples was performed
off-line by liquid-liquid extraction. The limit ofquantitation was 0.005 mg/l.
Statistics
All data were evaluated descriptively by calculating mean/median values and profiles.
The pharmacokinetic characteristics area under the curve (AUC) and t1/2 were evaluated
using standard methods [4].
RESULTS
Pharmacodynamics
Study 1: A single oral dose of 50 mg produced a rapid and steep increase in intra-
gastric pH. Within 30 to 60 min, pH values of about 6 were reached. Increasing the dose
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Figure 2. Median intragastric pH profiles in healthy male volunteers following single oral
doses ofBY841 (n = 6/dose).
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Figure 3. Median (n = 8) intragastric pH profiles in healthy male volunteers on the first and
seventh day oftreatment with 200 mg BY841 once a day.
led to a prolongation of the pH elevation without further increase in maximum pH values
([5], Figure 2).
Study 2: Single oral doses produced adose-dependent inhibition ofPSAO. Inhibition
was nearly complete at doses of200 mg or 400 mg. Inhibition ofthe secreted volume par-
alleled that ofacid output, but to a lesser extent ([6], Table 3).
Study 3: Intake of 100 mg both in themorning and in theevening rapidly raised intra-
gastric pH. The effect ofthe evening dose lasted longer than that ofthe morning dose. On
Day one, the effect of200 mg was superior to that of 100 mg, however, on Day seven there
238Wurst and Hartmann: Acid pump antagonists (reversible PPIs)
Table 3. Mean percent inhibition of PSAO and volume following single oral doses of BY 841
(n = 6 subjects each dose).
Percent inhibition vs. placebo
PSAO Volume
Group I 10 mg 11 12
20mg 27 26
Group II 50 mg 54 22
100 mg 62 47
Group III 200 mg 97 73
400 mg 100 91
was nearly no difference between the 100 mg morning and the 200 mg dose. The evening
dose of 100 mg produced a marked elevation of pH throughout the night even after the
first dose. In contrast, the 200 mg dose administered once daily in the morning showed
nearly no effect on nighttime pH. Thus, twice daily administration is more effective than
once a day administration of the same daily dose. With both treatment regimens, the
effect, particularly during the day, increased upon repeated dosing, the increase being
more pronounced with twice daily dosing ([7], Figures 3 and 4).
Study 4: In comparison to baseline values, both doses ofBY841, 50 mg twice daily
and 100 mg twice daily, markedly elevated intragastric pH and prolonged percent oftime
of pH > 4 even on Day 1. In contrast, only minor effects were observed with 20 mg
omeprazole once daily (Figure 5). Repeated daily administration led to an increase in sup-
pression ofintragastric acidity with all three treatment regimens. On Day 7, the effect of
50 mg and 100 mg BY841 twice daily was at least comparable to that of 20 mg omepra-
zole once daily (Table 4, Figure 6).
Pharmacokinetics
Study 2: BY841 was rapidly absorbed. Maximum serum concentrations were
attained between 0.5 and 1.5 hr following administration (Figure 7). Median Cmax- and
AUC-values increased with dose and ranged from 0.2 to 1.9 mg/l (Cmax) and from 0.3 to
4.1 mgxhll/ (AUC) for the doses 20 to 400 mg. BY841 was eliminated monophasically
from serum. Its serum elimination half-life was short, median values ranging from 1.1. to
1.7 hours.
Table 4. Median 24-hr pH and median percent oftime ofpH > 4 (n = 8).
Treatment Day 1 Day 7
Baseline: 1.5
Median pH 50 mg twice daily 1.1 3.1
100 mg twice daily 2.6 2.7
20 mg omeprazole 1.5 2.5
Baseline: 8.9
Median percent 50 mg twice daily 18.9 28.8
oftime pH > 4 100 mg twice daily 29.4 29.3
20 mg omeprazole 9.2 24.7
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Figure 4. Median (n = 8) intragastric pH profiles in healthy male volunteers on the first and
seventh day oftreatment with 100 mg BY841 twice daily.
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Figure 5. Median (n = 8) intragastric pH profiles in healthy male volunteers baseline and on
the first day oftreatment with 100 mg BY841 twice daily and omeprazole 20 mg once daily.
Study 3: Following repeated oral doses ofeither 100 mg twice daily or 200 mg daily,
AUC-values of BY841 on Day seven were slightly to moderately increased compared to
the values obtained on Day one for both dosing schemes (Figure 8).
AUC and Cmax of BY841 were higher following a 200 mg than one 100 mg dose,
although the increase was less than dose-proportional. T1/2 and tmax seemed to be inde-
pendent ofthe dose. The elimination half-life ofBY841 was unchanged following repeat-
ed doses at either dose level.
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Figure 6. Median (n = 12) intragastric pH profiles in healthy male volunteers baseline and on
theseventh day oftreatment with 100 mg BY841 twice daily and omeprazole 20 mg once daily.
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Figure 7. Mean (n = 6 each dose) serum concentration-time profiles of BY841 following single
oral doses ofBY841 in healthy male volunteers.
Safety and tolerability
In all the above-mentioned phase I trials, BY841 was well-tolerated. There were no
clinically relevant changes in vital signs, ECG or laboratory parameters.
DISCUSSION
The acid pump antagonist BY841 proved to be a potent antisecretory drug in man by
rapidly increasing intragastric pH up to values of about 6 even with a single oral dose of
50 mg. Higher doses caused a dose-dependent increase in duration of this pH elevation,
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Figure 8. MeanAUC ofBY841 on Day 1 and Day 7 oftreatment with 100 mg twice daily and
200 mg once daily BY841 in eight healthy male subjects.
without any additional increase in maximum pH values. Twice a day administration was
more effective than once daily morning administration of the same daily dose. The dura-
tion of the pH-elevating effect of BY841 further increased upon repeated daily adminis-
tration. This demonstrates lack of tolerance development, the latter being a well-known
disadvantage ofH2RAs (8).
As known from the literature (9), omeprazole shows low efficacy after the first dose
with increasing antisecretory effect to steady-state conditions upon repeated, once-daily
administration. In this intraindividual comparison to the standard dose ofomeprazole both
doses of BY841, 50 mg twice daily and 100 mg twice daily, were markedly more effec-
tive on Day one of treatment. Both doses proved to be as effective as omeprazole with
regard to median pH and percent of time at pH > 4 following repeated daily administra-
tion.
In duodenal ulcer, the pH threshold for optimal healing is 3 (10). Similar criteria
apply for gastric ulcer where the duration of treatment is important and the model of pH
3 holds good at eight weeks (11). For gastro-esophageal reflux disease the critical thresh-
old for intragastric pH is 4 at eight weeks (12). Hence, BY841 at a dose of 50 mg or 100
mg twice daily should be at least as effective in treatment ofpatients as the standard dose
of omeprazole. However, BY841 is markedly more effective in suppressing intragastric
acidity during the first days of treatment, a shortening of the healing time and an even
more rapid pain relief may be expected.
BY841 was rapidly absorbed. Cmax and AUC increased with increasing dose in the
dose range 20 to 400 mg. Its serum elimination, half-life was short and unchanged upon
repeated administration. Slightly increasedAUC-values upon repeated administration cor-
responded with an increase in the pharmacodynamic effect.
As to H. pylori eradication, administration ofBY841 in combination with one antibi-
otic should result in high and predictable pH values of about 6 in particular during the
period when maximum serum concentrations ofthe antibiotic are achieved. Profound acid
suppression seems to have asynergistic effect on H. pylori eradication (13). Whether dual
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therapy with BY841 and one antibiotic therefore improves H. pylori eradication remains
to be investigated in clinical trials.
Further advantages are that an acid pump antagonist such as BY841 is acid-stable and
hence, does not have to be protected from gastric acid by enteric coating. It acts irrespec-
tive ofthe activation state ofthe proton pump. The latter also means that a resting parietal
cell is inhibited and can not be subsequently stimulated to secrete acid.
In conclusion, BY841 is unique among the acid-suppressing drugs because it com-
bines the advantages ofboth H2RAs and proton pump inhibitors and should therefore fur-
ther improve the therapy of acid-related diseases.
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